← Back to patent-cliff list
APG-2449
Tier C — Watch / tradeAPG-2449
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ALK, ROS, FAK1
Indications (approved)：Non-small cell lung cancer, 间皮组织肿瘤, Ovarian cancer, Solid tumour, Oesophageal cancer
Regional status
US
-
EU
-
China
Phase III
2024-10-08
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of APG-2449?
Approved indications include: Non-small cell lung cancer, 间皮组织肿瘤, Ovarian cancer, Solid tumour, Oesophageal cancer.
When does the APG-2449 patent expire?
No public expiry year is available for APG-2449 yet; this page updates once verified.
How do I get a quote for APG-2449 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01